Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma

Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. Methods The relationships of TLSs with clinicopathological feat...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 22; no. 1; pp. 1 - 699
Main Authors Deguchi, Sota, Tanaka, Hiroaki, Suzuki, Shugo, Natsuki, Seji, Mori, Takuya, Miki, Yuichiro, Yoshii, Mami, Tamura, Tatsuro, Toyokawa, Takahiro, Lee, Shigeru, Muguruma, Kazuya, Wanibuchi, Hideki, Ohira, Masaichi
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 24.06.2022
BioMed Central
BMC
Subjects
Antibodies
Antitumor agents
B cell
Cancer therapies
CD20 antigen
CD23 antigen
CD8 antigen
Chemotherapy
Cloning
Development and progression
Drug therapy
Esophageal cancer
Esophageal squamous cell carcinoma
Esophagus
Flow cytometry
Health aspects
Immune checkpoint inhibitors
Immune response
Immunotherapy
Invasiveness
Lymphocytes
Lymphoid tissue
Medical prognosis
Metastasis
Patients
Prognosis
Squamous cell carcinoma
Statistical analysis
Surgery
Survival analysis
Tertiary lymphoid structures
Tumor-infiltrating lymphocytes
Tumors
Japan
United Kingdom > UK
United States > US
Online AccessGet full text

Cover

Abstract Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. Methods The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23.sup.+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8.sup.+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan-Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8.sup.+ cells was examined by Spearman's rank correlation coefficient test. Results TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. Conclusion TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma. Keywords: Esophageal squamous cell carcinoma, Tertiary lymphoid structures, B cell, Chemotherapy, Immunotherapy
AbstractList Abstract Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation.  Methods The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23 + cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8 + cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan–Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8 + cells was examined by Spearman’s rank correlation coefficient test. Results TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8 + cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8 + cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. Conclusion TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
BACKGROUNDTertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. METHODS: The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan-Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8+ cells was examined by Spearman's rank correlation coefficient test. RESULTSTLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. CONCLUSIONTLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
Abstract Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation.  Methods The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan–Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8+ cells was examined by Spearman’s rank correlation coefficient test. Results TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. Conclusion TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. Methods The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23.sup.+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8.sup.+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan-Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8.sup.+ cells was examined by Spearman's rank correlation coefficient test. Results TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. Conclusion TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma. Keywords: Esophageal squamous cell carcinoma, Tertiary lymphoid structures, B cell, Chemotherapy, Immunotherapy
Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23.sup.+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8.sup.+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan-Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8.sup.+ cells was examined by Spearman's rank correlation coefficient test. TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8.sup.+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs in esophageal squamous cell carcinoma, focusing on TLS maturation. Methods The relationships of TLSs with clinicopathological features of 236 patients who underwent curative surgery for stage 0-IV esophageal squamous cell carcinoma were investigated. Mature TLSs, in which the germinal center formation was rich in CD23+ cells, were classified as TLSs containing a germinal center (GC-TLSs). GC-TLS densities were measured, and CD8+ cells were counted. The prognostic impact of GC-TLSs was assessed by Kaplan–Meier plots using the log-rank test for the relapse-free survival. A comparative study of GC-TLSs was performed using the Wilcoxon rank sum test. The relationship between GC-TLSs and CD8+ cells was examined by Spearman’s rank correlation coefficient test. Results TLSs were located mainly at the invasive margin of the tumor in cases with esophageal squamous cell carcinoma. Among the patients treated with neoadjuvant chemotherapy, those with advanced disease had a better prognosis in the GC-TLS high-density group than did those in the GC-TLS low-density group. Patients in whom neoadjuvant chemotherapy was effective had more GC-TLSs than those in whom it was less effective. The density of GC-TLSs and the number of tumor-infiltrating CD8+ cells were higher in patients treated with neoadjuvant chemotherapy than in those without chemotherapy, and a weak correlation between the density of GC-TLSs and the number of tumor-infiltrating CD8+ cells was observed. Moreover, co-culturing of PBMCs with an anticancer drug-treated esophageal squamous cell carcinoma cell line increased the CD20 and CD23 expression in PBMCs in vitro. Conclusion TLS maturation may be important for evaluating the local tumor immune response in patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. The present results suggest that TLS maturation may be a useful target for predicting the efficacy of immunotherapy, including immune checkpoint inhibitor treatment for esophageal squamous cell carcinoma.
ArticleNumber 699
Audience Academic
Author Miki, Yuichiro
Deguchi, Sota
Suzuki, Shugo
Tanaka, Hiroaki
Natsuki, Seji
Ohira, Masaichi
Tamura, Tatsuro
Yoshii, Mami
Mori, Takuya
Lee, Shigeru
Muguruma, Kazuya
Toyokawa, Takahiro
Wanibuchi, Hideki
Author_xml – sequence: 1
  fullname: Deguchi, Sota
– sequence: 2
  fullname: Tanaka, Hiroaki
– sequence: 3
  fullname: Suzuki, Shugo
– sequence: 4
  fullname: Natsuki, Seji
– sequence: 5
  fullname: Mori, Takuya
– sequence: 6
  fullname: Miki, Yuichiro
– sequence: 7
  fullname: Yoshii, Mami
– sequence: 8
  fullname: Tamura, Tatsuro
– sequence: 9
  fullname: Toyokawa, Takahiro
– sequence: 10
  fullname: Lee, Shigeru
– sequence: 11
  fullname: Muguruma, Kazuya
– sequence: 12
  fullname: Wanibuchi, Hideki
– sequence: 13
  fullname: Ohira, Masaichi
BookMark eNptkk1r3DAQhk1JaT7aP9CToVDag1N92JZ0KYSlHwuBQtNDb2JWHu1qsaWNZGebf19tNrRxKTpIjJ55NTN6z4sTHzwWxWtKLimV7YdEmZRNRRiriBJCVPtnxRmtBa1YTcTJk_NpcZ7SlhAqJJEvilPeiIYSLs-Kn4veeWegLyP2eAfeYBlsOWIcHcT7sr8fdpvgujKNcTLjFDGVzpeYwm4Da8x56XaCIUypNNj3pYFonA8DvCyeW-gTvnrcL4qbz59-LL5W19--LBdX15VpZLuvbGcpKGy46GrLwRpJV7JrpBKIghJSCy4ZU0ygUl1ruARrJdbAVUME8ItieVTtAmz1LrohF60DOP0QCHGtIXdietRdK81qJYHVitVtLWXLFQOmCK5qyAVkrY9Hrd20GrAz6McI_Ux0fuPdRq_DnVaMcy5FFnj3KBDD7YRp1INLh6mAxzwgzVpJSc1lwzL65h90G6bo86AypWjDhKT8L7WG3IDzNuR3zUFUXwkiWf5GRjJ1-R8qrw4HZ7JlrMvxWcL7WUJmRvw1rmFKSS9vvs_Zt0_YTf7wcZNCP40u-DQH2RE0MaQU0f4ZHCX6YFd9tKvOdtUPdtV7_hvSZ9vQ
CitedBy_id crossref_primary_10_3389_fimmu_2023_1256355
crossref_primary_10_1631_jzus_B2200605
crossref_primary_10_3389_fimmu_2024_1369626
crossref_primary_10_1016_j_ccell_2023_02_017
crossref_primary_10_3389_fimmu_2023_1286850
crossref_primary_10_1038_s41416_023_02235_9
crossref_primary_10_1002_jmv_29386
crossref_primary_10_1186_s12885_023_11738_w
crossref_primary_10_3389_fimmu_2023_1188760
Cites_doi 10.1111/cas.14888
10.1002/JLB.5MA0720-710RRR
10.1007/s10388-016-0551-7
10.1158/0008-5472.CAN-17-1987
10.1038/s41571-020-0376-0
10.1038/s41467-021-23355-x
10.1007/s00428-020-02801-z
10.1016/j.immuni.2015.08.006
10.3389/fimmu.2021.648812
10.1007/s10388-016-0556-2
10.1111/imr.12405
10.1038/s41586-019-1922-8
10.1016/S0140-6736(12)60643-6
10.1016/j.jss.2017.03.033
10.1080/2162402X.2020.1724763
10.1038/s41368-020-00092-3
10.1080/2162402X.2021.1900635
10.1186/s12865-018-0251-2
10.1186/s12865-016-0167-7
10.1038/s41568-019-0144-6
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2022
DBID AAYXX
CITATION
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12885-022-09777-w
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic



Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 699
ExternalDocumentID oai_doaj_org_article_d68cbb8a2492464886392a290eb4ae53
A708235720
10_1186_s12885_022_09777_w
GeographicLocations Japan
United Kingdom--UK
United States--US
GeographicLocations_xml – name: Japan
– name: United Kingdom--UK
– name: United States--US
GroupedDBID ---
-A0
0R~
23N
2WC
3V.
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AFGXO
ABVAZ
AFNRJ
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c586w-fdf1a9e537d4f3afc81b8d5897ee7100473822927e99d6c38aff8e4a39507a3
IEDL.DBID RPM
ISSN 1471-2407
IngestDate Tue Oct 22 15:15:48 EDT 2024
Tue Sep 17 20:56:33 EDT 2024
Fri Oct 25 01:17:19 EDT 2024
Thu Oct 10 15:50:15 EDT 2024
Fri Feb 23 00:02:37 EST 2024
Fri Feb 02 04:14:52 EST 2024
Thu Aug 01 19:26:26 EDT 2024
Tue Aug 20 22:04:57 EDT 2024
Thu Sep 12 17:02:35 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c586w-fdf1a9e537d4f3afc81b8d5897ee7100473822927e99d6c38aff8e4a39507a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233387/
PMID 35751038
PQID 2691527813
PQPubID 44074
ParticipantIDs doaj_primary_oai_doaj_org_article_d68cbb8a2492464886392a290eb4ae53
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9233387
proquest_miscellaneous_2681043852
proquest_journals_2691527813
gale_infotracmisc_A708235720
gale_infotracacademiconefile_A708235720
gale_incontextgauss_ISR_A708235720
gale_healthsolutions_A708235720
crossref_primary_10_1186_s12885_022_09777_w
PublicationCentury 2000
PublicationDate 20220624
PublicationDateYYYYMMDD 2022-06-24
PublicationDate_xml – month: 6
  year: 2022
  text: 20220624
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC cancer
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AJ Gunderson (9777_CR8) 2021; 10
S Hiramatsu (9777_CR18) 2018; 19
S Japan Esophageal (9777_CR10) 2017; 14
H Li (9777_CR9) 2021; 12
S Japan Esophageal (9777_CR11) 2017; 14
NS Joshi (9777_CR13) 2015; 43
K Silina (9777_CR12) 2018; 78
T Mori (9777_CR5) 2021; 112
Q Li (9777_CR20) 2020; 12
K Yamaguchi (9777_CR14) 2020; 9
LRC Barros (9777_CR15) 2020; 108
AT Ruffin (9777_CR7) 2021; 12
Y Zhao (9777_CR6) 2020; 477
C Sautes-Fridman (9777_CR17) 2020; 17
MC Dieu-Nosjean (9777_CR2) 2016; 271
A Pennathur (9777_CR1) 2013; 381
C Sautes-Fridman (9777_CR3) 2019; 19
BA Helmink (9777_CR19) 2020; 577
C Sakimura (9777_CR4) 2017; 215
Y Wu (9777_CR16) 2016; 17
References_xml – volume: 112
  start-page: 1746
  issue: 5
  year: 2021
  ident: 9777_CR5
  publication-title: Cancer Sci
  doi: 10.1111/cas.14888
  contributor:
    fullname: T Mori
– volume: 108
  start-page: 1307
  issue: 4
  year: 2020
  ident: 9777_CR15
  publication-title: J Leukoc Biol
  doi: 10.1002/JLB.5MA0720-710RRR
  contributor:
    fullname: LRC Barros
– volume: 14
  start-page: 1
  issue: 1
  year: 2017
  ident: 9777_CR10
  publication-title: Esophagus
  doi: 10.1007/s10388-016-0551-7
  contributor:
    fullname: S Japan Esophageal
– volume: 78
  start-page: 1308
  issue: 5
  year: 2018
  ident: 9777_CR12
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-17-1987
  contributor:
    fullname: K Silina
– volume: 17
  start-page: 393
  issue: 7
  year: 2020
  ident: 9777_CR17
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-0376-0
  contributor:
    fullname: C Sautes-Fridman
– volume: 12
  start-page: 3349
  issue: 1
  year: 2021
  ident: 9777_CR7
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-23355-x
  contributor:
    fullname: AT Ruffin
– volume: 477
  start-page: 401
  issue: 3
  year: 2020
  ident: 9777_CR6
  publication-title: Virchows Arch
  doi: 10.1007/s00428-020-02801-z
  contributor:
    fullname: Y Zhao
– volume: 43
  start-page: 579
  issue: 3
  year: 2015
  ident: 9777_CR13
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.08.006
  contributor:
    fullname: NS Joshi
– volume: 12
  start-page: 648812
  year: 2021
  ident: 9777_CR9
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.648812
  contributor:
    fullname: H Li
– volume: 14
  start-page: 37
  issue: 1
  year: 2017
  ident: 9777_CR11
  publication-title: Esophagus
  doi: 10.1007/s10388-016-0556-2
  contributor:
    fullname: S Japan Esophageal
– volume: 271
  start-page: 260
  issue: 1
  year: 2016
  ident: 9777_CR2
  publication-title: Immunol Rev
  doi: 10.1111/imr.12405
  contributor:
    fullname: MC Dieu-Nosjean
– volume: 577
  start-page: 549
  issue: 7791
  year: 2020
  ident: 9777_CR19
  publication-title: Nature
  doi: 10.1038/s41586-019-1922-8
  contributor:
    fullname: BA Helmink
– volume: 381
  start-page: 400
  issue: 9864
  year: 2013
  ident: 9777_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60643-6
  contributor:
    fullname: A Pennathur
– volume: 215
  start-page: 74
  year: 2017
  ident: 9777_CR4
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2017.03.033
  contributor:
    fullname: C Sakimura
– volume: 9
  start-page: 1724763
  issue: 1
  year: 2020
  ident: 9777_CR14
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1724763
  contributor:
    fullname: K Yamaguchi
– volume: 12
  start-page: 24
  issue: 1
  year: 2020
  ident: 9777_CR20
  publication-title: Int J Oral Sci
  doi: 10.1038/s41368-020-00092-3
  contributor:
    fullname: Q Li
– volume: 10
  start-page: 1900635
  issue: 1
  year: 2021
  ident: 9777_CR8
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2021.1900635
  contributor:
    fullname: AJ Gunderson
– volume: 19
  start-page: 13
  issue: 1
  year: 2018
  ident: 9777_CR18
  publication-title: BMC Immunol
  doi: 10.1186/s12865-018-0251-2
  contributor:
    fullname: S Hiramatsu
– volume: 17
  start-page: 29
  issue: 1
  year: 2016
  ident: 9777_CR16
  publication-title: BMC Immunol
  doi: 10.1186/s12865-016-0167-7
  contributor:
    fullname: Y Wu
– volume: 19
  start-page: 307
  issue: 6
  year: 2019
  ident: 9777_CR3
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0144-6
  contributor:
    fullname: C Sautes-Fridman
SSID ssj0017808
Score 2.4528658
Snippet Abstract Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the...
Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the...
Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the significance of TLSs...
BACKGROUNDTertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the...
Abstract Background Tertiary lymphoid structures (TLSs) have been reported to be involved in immune responses in many carcinomas. This study investigated the...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 1
SubjectTerms Antibodies
Antitumor agents
B cell
Cancer therapies
CD20 antigen
CD23 antigen
CD8 antigen
Chemotherapy
Cloning
Development and progression
Drug therapy
Esophageal cancer
Esophageal squamous cell carcinoma
Esophagus
Flow cytometry
Health aspects
Immune checkpoint inhibitors
Immune response
Immunotherapy
Invasiveness
Lymphocytes
Lymphoid tissue
Medical prognosis
Metastasis
Patients
Prognosis
Squamous cell carcinoma
Statistical analysis
Surgery
Survival analysis
Tertiary lymphoid structures
Tumor-infiltrating lymphocytes
Tumors
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBQxC4oCsZh0_j21FVZDKgYK0N8uvwEolaQmrVf89M0521cCBC9d4LDnfeOyxZ_wNIW-izyHqVDOtgmYimZoZYzmLWgcZhEm8JNGcfVKnX8XHpVzeKPWFOWEjPfAI3EFSJoZgPDLbCQXTDbZU7rmtcxA-y5Hns7bbw9QUP9CmNtsnMkYdDLAKG3yJzFkNDo9mm9k2VNj6_16T_8yTvLHxnNwjdyePkR6OI71PbuXuAbl9NsXEH5LlRO15QbH-SYno076lGOtf-Z_X9OIaFNavEh2pYtdwvqarjmasXwCLCfQbrtYebwAo3uLTiNWFuv6Hf0TOT95_OT5lU70EFqVRG9amduEtYKKTaBvfRnBJTZLG6pyRxEfoBunduc7WJhUb49vWZOEbC06hbx6Tva7v8hNCE49NbHmAtU8IOG_44KOMUfom2Vp6W5F3W_Dc5UiK4cphwig3Qu0AalegdpuKHCG-O0kktC4fQM1uUrP7l5or8hK148bXoTuzdIcaQ4VS87oir4sEklp0mDXzza-HwX04_zwTejsJtT2oNPrpEQL8N_JgzST3Z5JgdXHevJ0mbrL6wXFlsUqwWcBwX-2asSdmsnUZNAkyZoHRV8kromfTawbQvKVbfS_M3-CNN43RT_8Hos_IHV4MQjEu9skezMH8HBysX-FFsaXfgs0kGw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NaxUxEA9aQbyIn7i2ahTBg4TuJtkke5IqlirUg1V4t5BNsvVB3W27fTz63zuTzXu6Cl43E5bMVyaZyW8Iee1dbL0OJdOq1UwGUzJjGs681m3dShN4KqI5_qKOvsvPi3qRL9zGXFa58YnJUYfB4x35PlcNdmA1lXh3fsGwaxRmV3MLjZvkVsVLhVqtF9sDV6VNaTYPZYzaH8EXG3yPzFkJYY9m69lmlDD7__XMf1dL_rH9HN4jd3PcSA8mQd8nN2L_gNw-zpnxh2SRAT7PKHZBSXl9OnQUM_5Ld3lNz65BbMMy0AkwdgWnbLrsacQuBuBSYN54sXJ4D0DxLp967DHUDz_dI3Jy-PHbhyOWuyYwXxu1Zl3oKtfEWuggO-E6D4GpCbVpdIwI5SO1QJB3rmPTBOWFcV1nonSigdDQicdkpx_6-ITQwL3wHW_BA0oJpw7XOl97XzsRmrJ2TUHebphnzydoDJuOFEbZidUWWG0Tq-26IO-Rv1tKhLVOH4bLU5utxAZlfNsahzCGUoFvgfiJO96UsZUOllSQFygdO70R3RqnPdCYMKw1LwvyKlEgtEWPtTOnbjWO9tPJ1xnRm0zUDSBS7_JTBFg3omHNKPdmlGB7fj68URObbX-0vzW1IC-3wzgT69n6CJIEGlNhDrbmBdEz9ZoxaD7SL38k_G-IyYUw-un_f75L7vCk6opxuUd2QLviMwigrtrnyUp-AbYfHDQ
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9QwDI_GkKa9ID7FwYCAkHhAhV6S5uMBoYGYBtJ4YEy6tyhN0nHS0bIrp-P-e-y0PVbYE6-NIzWO7Tix_TMhz72LpVchz5QsVSaCzjOtDcu8UmVRCh1YSqI5-SyPz8SnWTHbIUO7o56B7ZVXO-wndbZcvPp1sXkLCv8mKbyWr1uwsRrrjFmWgzujsvU1cp1hKRCm8ok_UQWlcz0Uzlw5b5_scQxE5FiucumcSnD-_xrtvxMpL51MRzfJjd6lpIedDNwiO7G-TfZO-qD5HTLrsT8XFBukpJA_bSqKyQBzt9zQxQZ2tJkH2mHJruACTuc1jdjgAKwNzGsvVg6fCCg-81OP7Yfq5ru7S06PPnx9f5z1DRUyX2i5zqpQTZ2JBVdBVNxVHnxWHQptVIyI8iMUR_x3pqIxQXquXVXpKBw34DU6fo_s1k0d7xMamOe-YiUYRyHgQuJK5wvvC8eDyQtnJuTlwDz7o0PNsOm2oaXtuG6B6zZx3a4n5B3yd0uJiNfpQ7M8t70C2SC1L0vtEOFQSDA74Foxx0weS-FgSRPyBHfHduWjW721hwpjiYVi-YQ8SxSIelFjWs25W7Wt_Xj6ZUT0oieqGthS7_oqBVg3AmWNKA9GlKCWfjw8iIkdpNoyabCNsJ7C7z7dDuNMTHWrI-wk0OgphmcLNiFqJF4jBo1H6vm3BA0O7jrnWj3475kPyT5LCiEzJg7ILghefARu18_ycdKl3-IvLQQ
  priority: 102
  providerName: Scholars Portal
Title Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma
URI https://www.proquest.com/docview/2691527813
https://search.proquest.com/docview/2681043852
https://pubmed.ncbi.nlm.nih.gov/PMC9233387
https://doaj.org/article/d68cbb8a2492464886392a290eb4ae53
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB6UvY58sa5dpY7CH4caRJUt-bEpLN0gp6QZhL0Jf7gKJ3TUNof_97hQ71NvbXvRgncC-L590dz8R8smZYJ30aSJzKxPuVZooVbDESWmF5cqzWEQzvswvfvBvUzHdIaLthYlF-87Ojqv54ria_Yq1lbcLN2jrxAZX41MISmBnJQe7ZBcUtN2iN6kDqVLVdseofLAEB6ywCZklKcQ6MlkfkP0Msw0p9qQ8-hlFzP5_PfPf1ZKPfj_nz8jTJm6kJ5v3e052QvWC7I-bzPhLMm0APucUb0GJeX1alxQz_jNz90DnDyC2eubpBjB2BbtsOqtowFsMwKXAuuXvlcFzAIpn-dThHUNVvTCvyPX52ffTi6S5NSFxQuXrpPTl0BRBZNLzMjOlg8BUeaEKGQJC-XCZIcg7k6EofO4yZcpSBW6yAkJDk70me1VdhTeEeuYyVzILHpBz2HUYa5xwTpjMF6kwRY98aZmnbzfQGDpuKVSuN1zXwHUdua7XPTJC_m4pEdY6PqjvbnQjXO1z5axVBmEMeQ6-BeInZliRBssNfFKPvEfp6E2P6NY49YnEhKGQLO2Rj5ECoS0qrJ25MavlUn-9nnSIPjdEZQ0idaZpRYDvRjSsDuVRhxJsz3WnWzXRje0vNcsLvCtYDeF1P2yncSXWs1UBJAk0aog5WMF6RHbUq8Og7gyYQ8T_btT_7X-vPCQHLBpEnjB-RPZA8cI7iK3ubR8sair75Mno7PJq0o8nFDCOuYJxMvrZj7b2B-piKok
link.rule.ids 230,315,730,783,787,867,888,2109,12069,21401,24331,27937,27938,31732,31733,33757,33758,43323,43818,53805,53807
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8RQphRqExAFZzdpO7JxQQVRb6PZAi7Q3y7GdslJJ2qarVf89M453ISBxjceKPC-PPeNvCHnrbKid8jlTZa2Y9DpnWlecOaXqopba81hEMzsup9_ll3kxTxdufSqrXPvE6Kh95_COfI-XFXZg1RPx4eKSYdcozK6mFhq3yR3E4UI9V_PNgWuidK7XD2V0udeDL9b4HpmzHMIexVajzShi9v_rmf-ulvxj-zl4SB6kuJHuD4J-RG6F9jG5O0uZ8SdkngA-zyl2QYl5fdo1FDP-C3t1Q89vQGzdwtMBMHYJp2y6aGnALgbgUmBef7m0eA9A8S6fOuwx1HY_7VNycvD59NOUpa4JzBW6XLHGNxNbhUIoLxthGweBqfaFrlQICOUjlUCQd65CVfnSCW2bRgdpRQWhoRXPyFbbteE5oZ474RpegweUEk4dtraucK6wwld5YauMvF8zz1wM0BgmHil0aQZWG2C1iaw2q4x8RP5uKBHWOn7ors5MshLjS-3qWluEMZQl-BaIn7jlVR5qaWFJGdlF6ZjhjejGOM2-woRhoXiekTeRAqEtWqydObPLvjeHJ99GRO8SUdOBSJ1NTxFg3YiGNaLcGVGC7bnx8FpNTLL93vzW1Iy83gzjTKxnawNIEmj0BHOwBc-IGqnXiEHjkXbxI-J_Q0wuhFbb___5Lrk3PZ0dmaPD468vyH0e1b5kXO6QLdC08BKCqev6VbSYXyDVHxs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSNVe-EYrDBYQEg8oTerEsfM4BtUGdJoYSBUvlr8yKtqkrKuq8ddz5yRVM972Wp-lOHe-3PV-9ztC3hrltOE2DnmmeZhaEYdC5DQ0nGumU2GpB9GMT7PjH-nnCZtsjfryoH2jp4NyNh-U018eW7mYm6jFiUVn4yMISiCz4tHCFtFdco8haXqbqDcFBC5i0fbIiCxaghsW2IpMwxgiHh6ud0kvwZpDjJ0pW58kz9z_v3--iZnc-giNHpCf7ePX2JPfg9WVHpi_N5gdb3W-h-R-E5oGh7XII3LHlY9Jb9wU35-QScMhOgtw0IqHDgRVESCoYKour4PZNVhGNbVBzUm7gkQ-mJaBw0EJ4LVg3_LPSuFfDQGWCwKDY4zKaq6ekvPRp-9Hx2EzmCE0TGTrsLDFUOWOJdymRaIKA7GvsEzk3DlkC0p5gjzylLs8t5lJhCoK4VKV5BB9quQZ2Smr0u2RwFKTmIJqcLJpComN0sowY5hKbB4zlffJ-1YzclGzb0iftYhM1iqVoFLpVSrXffIBlbeRROZs_0N1eSGb9yttJozWQiFTYpqB-4IQjSqax06nCo7UJweoelm3oW7uvzzkWJNknMZ98sZLIHtGifCcC7VaLuXJ-beO0LtGqKjAXoxquh3g3Ei41ZHc70jC9Tbd5dYGZeNelpJmOY4jFkN43NebZdyJkLnSgSZBRgyxzMton_CO7XZeUHcFLNJTjDcW-PzWOw9I7-zjSH49Of3yguxSf_GykKb7ZAds0L2ESO5Kv_J39h9fYEmk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+relevance+of+tertiary+lymphoid+structures+in+esophageal+squamous+cell+carcinoma&rft.jtitle=BMC+cancer&rft.au=Deguchi%2C+Sota&rft.au=Tanaka%2C+Hiroaki&rft.au=Suzuki%2C+Shugo&rft.au=Natsuki%2C+Seji&rft.date=2022-06-24&rft.pub=BioMed+Central&rft.eissn=1471-2407&rft.volume=22&rft_id=info:doi/10.1186%2Fs12885-022-09777-w&rft_id=info%3Apmid%2F35751038&rft.externalDBID=PMC9233387
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon